Regeneron Pharmaceuticals Inc. closed 44.49% short of its 52-week high of $1,211.20, which the company reached on August 27th ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 3% after the company's loss against Amgen (AMGN) and others in a patent case ...

We recently published a list of What Did Jim Cramer Say About These 19 Stocks Recently? In this article, we are going to take ...

Regeneron Pharmaceuticals Inc. closed 45.10% below its 52-week high of $1,211.20, which the company reached on August 27th.

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

A Bath High School senior will be competing on the international stage for her scientific research and invention. Our Conner ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The teen is the first student from Levittown's General Douglas MacArthur High School to be named a finalist in the ...

The Dermatology Foundation (DF) and the Skin of Color Society (SOCS) announce that Crystal U. Aguh, MD, FAAD, is the 2025 ...

EDT Regeneron (REGN) down 3% after appeals court decision in Amgen (AMGN) patent fightLight Up your Portfolio with Spark:Easily identify ...

This health education program aims to help patients living with COPD experience better health outcomes and improved quality of life for the duration of their lives.

Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses regulatory challenges for DB-OTO, Regeneron’s AAV-based gene therapy for hearing loss.